Glucocorticoid insensitive asthma: a one year clinical follow up pilot study

Pascal Demoly, Dany Jaffuel, Marc Mathieu, Hocine Sahla, Philippe Godard, François-Bernard Michel, Jean Bousquet

**Abstract**

**Background**—Glucocorticoid resistant or insensitive asthmatic subjects are usually defined as patients whose baseline pre-bronchodilation forced expiratory volume in one second (FEV₁) of less than 70–80% predicted improves significantly in response to β₂ agonists but by less than 15% following 1–2 weeks of 40 mg prednisolone daily. Since there is little long term clinical information on these patients, a one year prospective study was performed to assess whether glucocorticoid sensitivity may vary over time.

**Methods**—Nineteen severe asthmatic subjects were studied and received 40 mg prednisolone daily for seven days. Prednisolone was given for a further seven days in glucocorticoid insensitive asthmatics and then stopped. Patients were followed up for one year and the glucocorticoid test was repeated on five patients in each group six months later.

**Results**—Eleven patients were classified as glucocorticoid insensitive and eight as glucocorticoid sensitive on day 7. The demographic characteristics of the patients were similar in both groups. Four glucocorticoid insensitive patients became responsive after one further week of prednisolone treatment. Six months later, four of five glucocorticoid sensitive patients and three of five previously glucocorticoid insensitive patients were glucocorticoid sensitive.

**Conclusions**—Glucocorticoid sensitivity varies over time.


Keywords: glucocorticoid; asthma; resistance; sensitivity

Most patients with asthma improve during treatment with glucocorticoids. However, a few patients show little or no improvement in pulmonary function after a short course of oral steroids and are thus classified as glucocorticoid resistant (or insensitive). It has been proposed that a definition of glucocorticoid insensitive asthmatic subjects is a baseline morning pre-bronchodilator forced expiratory volume in one second (FEV₁) of less than 70–80% predicted, improving significantly in response to β₂ agonists but by less than 15% (from baseline values) following 40 mg prednisolone daily for 1–2 weeks. This subset of asthmatic patients is heterogeneous and there has been no long term follow up of them.

We therefore studied prospectively 19 severe asthmatics with a pre-bronchodilator FEV₁ of less than 80% predicted to assess whether glucocorticoid sensitivity varies over time.

**Methods**

Nineteen patients of mean (SD) age 47 (14) years fulfilled the American Thoracic Society definition of asthma and had improved their FEV₁ by more than 12% after inhalation of 200 µg salbutamol. They had severe asthma as defined by the AsthmExpert system and were managed according to asthma guidelines. They received high doses of inhaled glucocorticoids (2000 µg beclomethasone or equivalent) and long acting β₂ agonists and four patients were taking oral glucocorticoids in a daily dose of 7.5–15 mg. Beta agonists were stopped more than 12 hours before measurement of FEV₁. Compliance with treatment was controlled. Patients were not included if they had been admitted to hospital during the month preceding the study. The diagnosis of atopy, rhinitis, and sinusitis was based on a previous paper.

Patients received oral prednisolone 40 mg daily for seven days and were classified as glucocorticoid insensitive (or glucocorticoid sensitive) as defined above. Thereafter, glucocorticoid insensitive patients continued with oral prednisolone 40 mg daily for seven more days and FEV₁ was reassessed at day 14. Oral prednisolone was then discontinued and the patients were followed up for one year with their previous treatment according to asthma guidelines. Six months later the oral glucocorticoid test was repeated in 10 patients. Quantitative results are given as mean (SD) values.

**Results**

Eleven patients (eight men) were classified as glucocorticoid insensitive (ΔFEV₁, 4.3 (4.6)% at day 7 and eight patients (seven men) were classified as glucocorticoid sensitive (ΔFEV₁, 44.2 (18.9)%; fig 1A). At entry to the study these two groups of patients were no different.
in terms of asthma severity (AsthmExpert® score of 5), pre-bronchodilation FEV₁ (53.1 (17.6)% and 66.8 (11.4)% predicted; fig 1B), improvement in FEV₁ after 200 µg salbutamol (13.5 (8.3)% and 19.5 (16.1)% from baseline).

They did not differ in mean age (47 (16) and 48 (14) years), duration of asthma (18 (11) and 15 (9) years), presence of atopy (11/11 and 5/8 with seasonal exacerbations in 3/11 and 1/5), or rhinosinusitis (8/11 and 6/8). Two patients in both groups were glucocorticoid dependent.

After seven days of treatment with prednisolone most glucocorticoid insensitive asthmatics remained sensitive to salbutamol (21.5 (20.5)% from baseline) compared with glucocorticoid sensitive patients (4.9 (6.5)% from baseline) whose FEV₁ had probably improved to their maximum.

By prolonging prednisolone treatment for one week four of 11 glucocorticoid insensitive patients became glucocorticoid sensitive. The oral glucocorticoid test was repeated six months later in five patients in each group and one of five previously glucocorticoid sensitive patients became glucocorticoid insensitive. Conversely, three of five previously glucocorticoid insensitive patients became glucocorticoid sensitive.

During the one year follow up, mild to moderate asthma exacerbations (1.9 (1.9) and 1.5 (1.3) episodes in glucocorticoid insensitive and sensitive patients, respectively) and severe exacerbations requiring admission to hospital (0.4 (0.7) and 0.6 (1.4) episodes, respectively) were similar in the two groups.

**Discussion**

Glucocorticoid resistance or insensitivity may vary over time and this is important since it has been suggested that inflammation may contribute to a lack of response to glucocorticoid, in particular after allergen challenge. Although no definition of glucocorticoid insensitivity is ideal, the pragmatic definition of an “improvement in FEV₁ of less than 15% after an adequate dose (40 mg) of oral glucocorticoid such as prednisolone for an adequate duration of time (1–2 weeks)” has recently been proposed, whether or not the patients are already taking daily oral glucocorticoids. In our study we have shown (some authors have only suggested) that two weeks of treatment with prednisolone may be more suitable than one week since four of 11 so called glucocorticoid insensitive asthmatic subjects after seven days of treatment with oral glucocorticoid were no longer glucocorticoid insensitive after 14 days of treatment.

Not only is the duration of treatment important but the dose could also be crucial and there are very few large scale data on both duration and dose-response relationships between glucocorticoid and lung function. Patients who are insensitive to 40 mg glucocorticoid may respond to higher doses, although during acute asthma exacerbations higher doses have not shown greater efficacy. It is possible that other oral glucocorticoids may be more effective as there is some evidence that methylprednisolone is distributed better into the lungs than prednisolone. In glucocorticoid dependent asthmatic subjects a comparison of these three oral glucocorticoids did not show any clinical differences in one study, although betamethasone was reported to produce a better improvement in FEV₁ than prednisolone in another study.

A practical definition of glucocorticoid insensitivity based on both FEV₁ and symptom scores during a sufficiently long follow up period would be more useful for physicians. For research purposes the current clinical defi-
Glucocorticoid insensitive asthma

niton, which may allow basic researchers to elucidate some of the mechanisms of action of glucocorticoids and asthma pathophysiology, possibly allowing the development of a routine laboratory test to predict glucocorticoid response and to help in the development of novel anti-asthma therapies, should take our results into account.

Glucocorticoid insensitive asthma: a one year clinical follow up pilot study

Pascal Demoly, Dany Jaffuel, Marc Mathieu, Hocine Sahla, Philippe Godard, François-Bernard Michel and Jean Bousquet

Thorax 1998 53: 1063-1065
doi: 10.1136/thx.53.12.1063